You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 64 No. 3, March 2007 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Observation
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (99)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Alzheimer Disease
 •Lewy Body Disease
 •Movement Disorders
 •Neurology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy

A Case Report

Brian J. Bacskai, PhD; Matthew P. Frosch, MD, PhD; Stefanie H. Freeman, MD; Scott B. Raymond, BS; Jean C. Augustinack, PhD; Keith A. Johnson, MD; Michael C. Irizarry, MD; William E. Klunk, MD, PhD; Chester A. Mathis, PhD; Steven T. DeKosky, MD; Steven M. Greenberg, MD, PhD; Bradley T. Hyman, MD, PhD; John H. Growdon, MD

Arch Neurol. 2007;64(3):431-434.

Objective  To determine the correspondence between uptake of Pittsburgh Compound B (PiB) in life and measures of β-amyloid (Aβ) in postmortem tissue analysis.

Patient  A 76-year-old man with a clinical diagnosis of dementia with Lewy bodies underwent fluorodeoxyglucose 18F and PiB positron emission tomographic brain scans. Imaging revealed marked region specific binding of PiB and abnormal fluorodeoxyglucose uptake.

Intervention  Autopsy was performed 3 months after the PiB scan.

Results  Autopsy confirmed the clinical diagnosis; in addition, there was severe cerebral amyloid angiopathy and only moderate numbers of parenchymal Aβ plaques. Biochemical measures revealed a positive correlation between Aβ levels and regional PiB binding.

Conclusion  This report confirms that PiB detects Aβ in the living patient and demonstrates that amyloid deposited as cerebral amyloid angiopathy can be the dominant source of signal.


Author Affiliations: MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Charlestown, Mass (Drs Bacskai, Frosch, Irizarry, Greenberg, Hyman, and Growdon and Mr Raymond); C. S. Kubik Laboratory for Neuropathology (Drs Frosch and Freeman) and Department of Radiology (Drs Augustinack and Johnson), Massachusetts General Hospital, Boston; and Departments of Psychiatry (Drs Klunk and Mathis) and Neurology (Dr DeKosky), University of Pittsburgh, Pittsburgh, Pa. Dr Irizarry is now with GlaxoSmithKline, Research Triangle Park, NC.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Pittsburgh Compound B Retention and Verification of Amyloid Deposition
David M. Holtzman
Arch Neurol. 2007;64(3):315-316.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum
Charidimou et al.
J. Neurol. Neurosurg. Psychiatry 2012;83:124-137.
ABSTRACT | FULL TEXT  

Brain Amyloid Imaging
Rowe and Villemagne
JNM 2011;52:1733-1740.
ABSTRACT | FULL TEXT  

Association Between In Vivo Fluorine 18-Labeled Flutemetamol Amyloid Positron Emission Tomography Imaging and In Vivo Cerebral Cortical Histopathology
Wolk et al.
Arch Neurol 2011;68:1398-1403.
ABSTRACT | FULL TEXT  

Subtypes of progressive aphasia: application of the international consensus criteria and validation using {beta}-amyloid imaging
Leyton et al.
Brain 2011;134:3030-3043.
ABSTRACT | FULL TEXT  

Cerebral microhemorrhage and brain {beta}-amyloid in aging and Alzheimer disease
Yates et al.
Neurology 2011;77:48-54.
ABSTRACT | FULL TEXT  

Using Positron Emission Tomography and Carbon 11-Labeled Pittsburgh Compound B to Image Brain Fibrillar {beta}-Amyloid in Adults With Down Syndrome: Safety, Acceptability, and Feasibility
Landt et al.
Arch Neurol 2011;68:890-896.
ABSTRACT | FULL TEXT  

Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution
Rosenbloom et al.
Neurology 2011;76:1789-1796.
ABSTRACT | FULL TEXT  

In Vivo Fibrillar {beta}-Amyloid Detected Using [11C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults
Sojkova et al.
Arch Neurol 2011;68:232-240.
ABSTRACT | FULL TEXT  

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease
Kadir et al.
Brain 2011;134:301-317.
ABSTRACT | FULL TEXT  

Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia
Kadir and Nordberg
JNM 2010;51:1418-1430.
ABSTRACT | FULL TEXT  

Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18 F-FDG) PET in Patients With Alzheimer Disease, Mild Cognitive Impairment, and Healthy Controls
Devanand et al.
J Geriatr Psychiatry Neurol 2010;23:185-198.
ABSTRACT  

Sharpen That Needle
Herskovits and Growdon
Arch Neurol 2010;67:918-920.
FULL TEXT  

Imaging Approaches to Parkinson Disease
Brooks
JNM 2010;51:596-609.
ABSTRACT | FULL TEXT  

11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage
Ly et al.
Neurology 2010;74:487-493.
ABSTRACT | FULL TEXT  

Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden
Rabinovici et al.
Brain 2010;133:512-528.
ABSTRACT | FULL TEXT  

Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.
Cairns et al.
Arch Neurol 2009;66:1557-1562.
ABSTRACT | FULL TEXT  

Clinical syndromes associated with posterior atrophy: Early age at onset AD spectrum
Migliaccio et al.
Neurology 2009;73:1571-1578.
ABSTRACT | FULL TEXT  

Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden
Hedden et al.
J. Neurosci. 2009;29:12686-12694.
ABSTRACT | FULL TEXT  

11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease
Villemagne et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:998-1001.
ABSTRACT | FULL TEXT  

Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease
Nelissen et al.
JNM 2009;50:1251-1259.
ABSTRACT | FULL TEXT  

{beta}-Amyloid, Blood Vessels, and Brain Function
Smith and Greenberg
Stroke 2009;40:2601-2606.
ABSTRACT | FULL TEXT  

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Jack et al.
Brain 2009;132:1355-1365.
ABSTRACT | FULL TEXT  

In vivo mapping of amyloid toxicity in Alzheimer disease
Frisoni et al.
Neurology 2009;72:1504-1511.
ABSTRACT | FULL TEXT  

Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease
Buckner et al.
J. Neurosci. 2009;29:1860-1873.
ABSTRACT | FULL TEXT  

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography
Edison et al.
J. Neurol. Neurosurg. Psychiatry 2008;79:1331-1338.
ABSTRACT | FULL TEXT  

Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist
Klunk
Arch Neurol 2008;65:1281-1283.
FULL TEXT  

Assessment of {beta}-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11-Labeled Pittsburgh Compound B
Leinonen et al.
Arch Neurol 2008;65:1304-1309.
ABSTRACT | FULL TEXT  

Imaging amyloid deposition in Lewy body diseases
Gomperts et al.
Neurology 2008;71:903-910.
ABSTRACT | FULL TEXT  

Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern?
Sojkova et al.
JNM 2008;49:1465-1471.
ABSTRACT | FULL TEXT  

PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease
Koivunen et al.
Brain 2008;131:1845-1853.
ABSTRACT | FULL TEXT  

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic et al.
Brain 2008;131:1630-1645.
ABSTRACT | FULL TEXT  

Carbon 11-Labeled Pittsburgh Compound B Positron Emission Tomographic Amyloid Imaging in Patients With APP Locus Duplication
Remes et al.
Arch Neurol 2008;65:540-544.
ABSTRACT | FULL TEXT  

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment
Jack et al.
Brain 2008;131:665-680.
ABSTRACT | FULL TEXT  

PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis
Lockhart et al.
Brain 2007;130:2607-2615.
ABSTRACT | FULL TEXT  

A{beta} amyloid deposition in the language system and how the brain responds
Nelissen et al.
Brain 2007;130:2055-2069.
ABSTRACT | FULL TEXT  

Pittsburgh Compound B Retention and Verification of Amyloid Deposition
Holtzman
Arch Neurol 2007;64:315-316.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.